Novel Therapeutics for Long QT Syndrome
Novel Therapeutics for Long QT Syndrome
批准号:
10705357
负责人:
Masayuki Yazawa
金额:
$24.55万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-22 至 2023-06-30
关键词:
Action PotentialsAddressAdverse effectsAgonistArrhythmiaBiological AssayBirthBlood - brain barrier anatomyBrainCDC2 geneCalcium ChannelCardiacCardiac MyocytesCell modelChemicalsClientClinicalCoughingCouplingCyclin-Dependent Kinase 5DextromethorphanDiseaseDisease modelElectrocardiogramElectrophysiology (science)Excretory functionFDA approvedFunctional disorderGene ExpressionGeneticGenetic ModelsGoalsHeartHepatotoxicityHumanHypoglycemiaIn VitroInduced MutationInfantIon ChannelLeadLifeLong QT SyndromeLongevityMetabolismMitochondriaModelingMolecularMolecular ChaperonesMusMuscle CellsN-Methyl-D-Aspartate ReceptorsNamesNeuraxisNeuronsOrganPancreasPatientsPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePhenotypePhysiologicalPlayProteinsProteomicsReceptor ActivationRegulationReportingRodent ModelRoleSelective Serotonin Reuptake InhibitorSpecificitySyndromeTestingTherapeuticTimothy syndromeTissuesWorkabsorptionantagonistautism spectrum disorderbasecancer clinical trialdesigndrug candidatedrug developmentdrug testingexperimental studygain of function mutationgenetic approachheart functionin vivoinduced pluripotent stem cellinhibitorinsightinsulin secretionmouse modelnew technologynovel therapeuticsoverexpressionpreventreceptor bindingside effectsigma-1 receptorsmall moleculestem cell modeltherapeutic candidatetherapeutic targettranslational applicationstranslational approachtranslational studytrial designvoltage
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary:
Abnormal ion channel function in heart muscle cells induces cardiac arrhythmias such as long QT syndrome.
In preliminary experiments using pharmaceutical approach, we found that activation of Sigma 1 receptor could
alleviate the cellular phenotypes in human induced pluripotent stem cell (iPSC) and mouse models of the
genetic cardiac arrhythmias. The goal of this study is to examine the molecular mechanism underlying the
beneficial effect of Sigma receptor 1 activation on the phenotypes in cardiac ion channel regulation, action
potentials, contraction, mitochondrial function and gene expression in the genetic arrhythmia models. We will
use human iPSC and rodent models to accomplish our goal. In addition, we will design and develop new
Sigma 1 receptor agonists that are more suitable for cardiac arrhythmias, taking advantage of our expertise in
medicinal chemistry. Therefore, our translational study will provide new opportunity of drug development for the
genetic syndromic disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutics for Timothy Syndrome and Related Cardiac Channelopathy
-
批准号:10911506
-
项目类别:
-
资助金额:$70.94万
-
财政年份:2023
-
负责人:Masayuki Yazawa
-
依托单位:
Novel Therapeutics for Long QT Syndrome
-
批准号:10897465
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2022
-
负责人:Masayuki Yazawa
-
依托单位:
Molecular mechanisms underlying cardiac sodium channelopathy
-
批准号:10199772
-
项目类别:
-
资助金额:$39.76万
-
财政年份:2017
-
负责人:Masayuki Yazawa
-
依托单位:
Molecular mechanisms underlying cardiac sodium channelopathy
-
批准号:9974589
-
项目类别:
-
资助金额:$39.66万
-
财政年份:2017
-
负责人:Masayuki Yazawa
-
依托单位:
Model of Timothy Syndrome to Screen Drugs with Induced Pluripotent Stem Cells
-
批准号:8399063
-
项目类别:
-
资助金额:$8.63万
-
财政年份:2012
-
负责人:Masayuki Yazawa
-
依托单位:
Model of Timothy Syndrome to Screen Drugs with Induced Pluripotent Stem Cells
-
批准号:8811467
-
项目类别:
-
资助金额:$24.4万
-
财政年份:2012
-
负责人:Masayuki Yazawa
-
依托单位:
Model of Timothy Syndrome to Screen Drugs with Induced Pluripotent Stem Cells
-
批准号:8626438
-
项目类别:
-
资助金额:$24.4万
-
财政年份:2012
-
负责人:Masayuki Yazawa
-
依托单位:
Model of Timothy Syndrome to Screen Drugs with Induced Pluripotent Stem Cells
-
批准号:8598272
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2012
-
负责人:Masayuki Yazawa
-
依托单位:
Model of Timothy Syndrome to Screen Drugs with Induced Pluripotent Stem Cells
-
批准号:8226405
-
项目类别:
-
资助金额:$8.63万
-
财政年份:2012
-
负责人:Masayuki Yazawa
-
依托单位:
海外基金